Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving outcomes in chronic heart failure.

Michel Komajda1

  • 1Institut de Cardiologie, Hopital Pitie-Salpetriere, Universite Pierre et Marie Curie, Paris, France.

Drugs of Today (Barcelona, Spain : 1998)
|January 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis.

European heart journal·2026
Same author

[Physical Activity while wearing a Mask : A Comparison of Respiratory Parameters During Submaximal Exercise between Surgical, Cloth Masks and Sham Masks ; The PAM study].

Annales de cardiologie et d'angeiologie·2025
Same author

Progression of cardiac dysfunction in patients with type 2 diabetes without overt cardiovascular disease: A three-year follow-up echocardiographic study (DIACAR).

Diabetes, obesity & metabolism·2025
Same author

Ivabradine improves win ratios of heart failure outcomes in patients with reduced ejection fraction - insights from the SHIFT trial.

European journal of heart failure·2025
Same author

Prediction of 90 day mortality in elderly patients with acute HF from e-health records using artificial intelligence.

ESC heart failure·2025
Same author

Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial.

JACC. Heart failure·2025

Angiotensin receptor blockers (ARBs) like candesartan significantly reduce cardiovascular death and heart failure hospitalizations in patients. ARBs also lower the risk of new-onset diabetes and atrial fibrillation.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Recent trials of angiotensin receptor blockers (ARBs) necessitate updates to European Society of Cardiology chronic heart failure management guidelines.
  • The CHARM program's trials are pivotal in evaluating ARBs, specifically candesartan, in heart failure patients.

Purpose of the Study:

  • To assess the efficacy of candesartan in managing chronic heart failure across different patient subgroups.
  • To evaluate the impact of candesartan on cardiovascular outcomes, new-onset diabetes, and atrial fibrillation.

Main Methods:

  • The study analyzed data from three CHARM program trials (CHARM-Alternative, CHARM-Added, CHARM-Preserved) comparing candesartan to placebo.
  • Patients included those intolerant to ACE inhibitors, those on ACE inhibitors, and those with preserved ejection fraction.

Related Experiment Videos

Main Results:

  • Candesartan significantly reduced cardiovascular death or heart failure hospitalization in patients intolerant to ACE inhibitors (CHARM-Alternative).
  • This risk reduction was also significant in patients already on ACE inhibitors (CHARM-Added).
  • A borderline significant risk reduction was observed in patients with preserved ejection fraction (CHARM-Preserved). Candesartan also reduced new-onset diabetes and atrial fibrillation risk (CHARM-Overall).

Conclusions:

  • Candesartan is effective in reducing adverse cardiovascular events in various chronic heart failure populations.
  • The findings support the use of ARBs, specifically candesartan, in updating heart failure treatment guidelines.
  • Candesartan demonstrates broader benefits, including reduced incidence of new-onset diabetes and atrial fibrillation.